- Home
- Mutual Funds
- Edelweiss Mutual Fund
- Edelweiss Msci India Domestic & World Healthcare 45 Index Fund Direct-idcw
Fund Overview of Edelweiss Msci India Domestic & World Healthcare 45 Index Fund Direct-idcw
-
₹178.1 CrAUM
-
₹22.52NAV
-
0.51%Expense Ratio
-
EquityFund Category
Minimum amount you can invest: ₹500
Maximum amount you can invest: ₹1,00,000
We have used a return rate of 15% for our calculations.
Returns of Edelweiss Msci India Domestic & World Healthcare 45 Index Fund Direct-idcw
| Tenure | Absolute(%) | Annualised(%) | Category Average(%) |
|---|---|---|---|
| 3 Months | 5.77% | NA | 6.12% |
| 6 Months | 5.24% | NA | 12.92% |
| 1 Year | 12.49% | 12.49% | 6.04% |
| 2 Years | 22.95% | 10.88% | 24.93% |
| 3 Years | 69.86% | 19.31% | 25.71% |
| 5 Years | 83.06% | 12.85% | 19.91% |
Compare Edelweiss Msci India Domestic & World Healthcare 45 Index Fund Direct-idcw with other mutual funds in the same category
Edelweiss Msci India Domestic & World Healthcare 45 Index Fund Direct-idcw
SBI Healthcare Opportunities Fund Direct Plan-growth
SBI Healthcare Opportunities Fund Direct Plan-idcw
Asset Allocation
equities
99.67%debt instruments
0.30%other assets or cash equivalents
0.03%Edelweiss Msci India Domestic & World Healthcare 45 Index Fund Direct-idcw is one Equity mutual fund offered by Edelweiss Mutual Fund. Launched on 26 Oct 2020, the fund aims Long Term Capital appreciation. Passive investment in equity and equity related securities replicating the composition of MSCI India Domestic & World Healthcare 45 Index, subject to tracking error. It manages assets worth ₹178.1 crore as on Sun May 31, 2026. The expense ratio stands at 0.51%. Fund Manager Manager Education Fund Manager Manager EducationAbout Edelweiss Msci India Domestic & World Healthcare 45 Index Fund Direct-idcw
The portfolio allocation consists of 99.67% in equities, 0.30% in debt instruments, 0.03% in other assets or cash equivalents.Managed by Amit Vora, it has delivered a return of 12.49% in the last year, a total return since inception of 15.48%.
Selecting an appropriate best sip plays a vital role for financial planning.
Key Metrics of Edelweiss Msci India Domestic & World Healthcare 45 Index Fund Direct-idcw
-
Standard Deviation12.54%
-
Sharpe Ratio1.14%
-
Alpha1.58%
-
Beta0.66%
Fund Details
|
|
Top Performing Mutual Funds
| Fund Names | AUM (Cr) | 1M | 3M | 1Yr | 3Yr | 5Yr |
|---|---|---|---|---|---|---|
SBI Healthcare Opportunities Fund Direct Plan-growth  |
₹4,566 | 1.67% | 13.30% | 10.49% | 24.74% | 16.80% |
| SBI Healthcare Opportunities Fund Direct Plan-idcw |
₹4,566 | 1.67% | 13.30% | 10.49% | 24.74% | 16.80% |
ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-growth  |
₹6,454 | -1.21% | 11.20% | 7.32% | 26.34% | 16.48% |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-idcw |
₹6,454 | -1.21% | 11.20% | 7.32% | 26.34% | 16.48% |
| Mirae Asset Healthcare Fund Direct-growth |
₹3,091 | -0.79% | 9.54% | 13.22% | 24.88% | 15.73% |
| Mirae Asset Healthcare Fund Direct-idcw |
₹3,091 | -0.79% | 9.54% | 13.22% | 24.88% | 15.73% |
| DSP Healthcare Fund Direct-growth |
₹3,309 | 3.03% | 14.21% | 8.50% | 22.68% | 15.62% |
| DSP Healthcare Fund Direct-idcw |
₹3,309 | 3.03% | 14.21% | 8.50% | 22.68% | 15.62% |
| SBI Healthcare Opportunities Fund-growth |
₹4,566 | 1.58% | 13.02% | 9.38% | 23.45% | 15.57% |
| SBI Healthcare Opportunities Fund-idcw |
₹4,566 | 1.58% | 13.02% | 9.38% | 23.45% | 15.57% |
growth is based on 1-month returns of the funds & Top fund are based on 3Y Returns
More funds from Edelweiss Mutual Fund
| Fund Names | AUM (Cr) | 1M | 3M | 6M | 1Yr | 3Yr |
|---|---|---|---|---|---|---|
|
Edelweiss Msci India Domestic & World Healthcare 45 Index Fund Direct-growth
|
₹178 | 0.02% | 5.77% | 5.24% | 12.49% | 19.31% |
|
Edelweiss Msci India Domestic & World Healthcare 45 Index Fund Regular-growth
|
₹178 | -0.03% | 5.63% | 4.96% | 11.89% | 18.66% |
|
Edelweiss Msci India Domestic & World Healthcare 45 Index Fund Regular-idcw
|
₹178 | -0.03% | 5.63% | 4.96% | 11.89% | 18.66% |
growth is based on 1-month returns of the fundsMutual Fund Calculator
- 1
- 2
- 3
- 4
- 6
- 7
- 8
- 9
- 11
- 12
- 13
- 14
- 16
- 17
- 18
- 19
- 21
- 22
- 23
- 24
- 26
- 27
- 28
- 29
- 31
- 32
- 33
- 34
- 36
- 37
- 38
- 39
- 40
- 1
- 2
- 3
- 4
- 6
- 7
- 8
- 9
- 11
- 12
- 13
- 14
- 16
- 17
- 18
- 19
- 21
- 22
- 23
- 24
- 26
- 27
- 28
- 30
- 1
- 2
- 3
- 4
- 6
- 7
- 8
- 9
- 11
- 12
- 13
- 14
- 16
- 17
- 18
- 19
- 21
- 22
- 23
- 24
- 26
- 27
- 28
- 29
- 31
- 32
- 33
- 34
- 36
- 37
- 38
- 39
- 40
- 1
- 2
- 3
- 4
- 6
- 7
- 8
- 9
- 11
- 12
- 13
- 14
- 16
- 17
- 18
- 19
- 21
- 22
- 23
- 24
- 26
- 27
- 28
- 30
Top Mutual Funds
| Fund Names | AUM (Cr) | NAV | 3Yr | 5Yr | 10Yr |
|---|---|---|---|---|---|
| Nippon India Pharma Fund-growth |
₹8,636 | ₹535.25 | 20.43% | 12.64% | 15.21% |
| Nippon India Pharma Fund Direct-growth |
₹8,636 | ₹601.05 | 21.51% | 13.66% | 16.24% |
| Nippon India Pharma Fund-idcw |
₹8,636 | ₹115.58 | 20.43% | 12.64% | 15.21% |
| Nippon India Pharma Fund Direct-idcw |
₹8,636 | ₹164.49 | 21.51% | 13.66% | 16.24% |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund-growth |
₹6,454 | ₹41.36 | 25.28% | 15.47% | - |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-growth |
₹6,454 | ₹44.89 | 26.34% | 16.48% | - |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund-idcw |
₹6,454 | ₹24.13 | 25.28% | 15.47% | - |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-idcw |
₹6,454 | ₹27.11 | 26.34% | 16.48% | - |
| SBI Healthcare Opportunities Fund-growth |
₹4,566 | ₹468.57 | 23.45% | 15.57% | 13.35% |
| SBI Healthcare Opportunities Fund Direct Plan-growth |
₹4,566 | ₹541.52 | 24.74% | 16.80% | 14.59% |
Detailed Portfolio
| Stocks | Sector | % of Holding | Value |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | Healthcare | 11.42% | ₹20.34 Cr |
| Eli Lilly Forgn. Eq (lly) | Healthcare | 6.50% | ₹11.57 Cr |
| Apollo Hospitals Enterprise Ltd | Healthcare | 5.83% | ₹10.39 Cr |
| Divi's Laboratories Ltd | Healthcare | 5.27% | ₹9.38 Cr |
| Cipla Ltd | Healthcare | 5.24% | ₹9.33 Cr |
| Max Healthcare Institute Ltd | Healthcare | 4.97% | ₹8.85 Cr |
| Dr. Reddy's Laboratories Ltd | Healthcare | 4.68% | ₹8.33 Cr |
| Johnson & Johnson Ltd. Forgn. Eq (jnj) | Healthcare | 3.94% | ₹7.02 Cr |
| Lupin Ltd | Healthcare | 3.77% | ₹6.71 Cr |
| Torrent Pharmaceuticals Ltd | Healthcare | 3.46% | ₹6.16 Cr |
| Laurus Labs Ltd | Healthcare | 3.16% | ₹5.63 Cr |
| Fortis Healthcare Ltd | Healthcare | 3.01% | ₹5.37 Cr |
| Abbvie Inc Forgn. Eq (abbv) | Healthcare | 2.79% | ₹4.98 Cr |
| Aurobindo Pharma Ltd | Healthcare | 2.47% | ₹4.39 Cr |
| Glenmark Pharmaceuticals Ltd | Healthcare | 2.34% | ₹4.16 Cr |
| Merck & Co Inc (us) Forgn. Eq (mrk) | Healthcare | 2.14% | ₹3.81 Cr |
| Novartis Ag Ads/adr (nvs) | Healthcare | 2.07% | ₹3.69 Cr |
| Mankind Pharma Ltd. | Healthcare | 1.95% | ₹3.47 Cr |
| Alkem Laboratories Ltd | Healthcare | 1.74% | ₹3.10 Cr |
| Biocon Ltd | Healthcare | 1.71% | ₹3.05 Cr |
Top Equity Funds
| Fund Names | NAV | 3Yr | 5Yr | 52 weeks high |
|---|---|---|---|---|
| SBI Healthcare Opportunities Fund Direct Plan-growth |
₹541.52 | 24.74% | 16.80% | - |
| SBI Healthcare Opportunities Fund Direct Plan-idcw |
₹376.23 | 24.74% | 16.80% | - |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-growth |
₹44.89 | 26.34% | 16.48% | - |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-idcw |
₹27.11 | 26.34% | 16.48% | - |
| Mirae Asset Healthcare Fund Direct-growth |
₹47.24 | 24.88% | 15.73% | - |
| Mirae Asset Healthcare Fund Direct-idcw |
₹28.45 | 24.88% | 15.73% | - |
| DSP Healthcare Fund Direct-growth |
₹46.19 | 22.68% | 15.62% | - |
| DSP Healthcare Fund Direct-idcw |
₹26.71 | 22.68% | 15.62% | - |
| SBI Healthcare Opportunities Fund-growth |
₹468.57 | 23.45% | 15.57% | - |
| SBI Healthcare Opportunities Fund-idcw |
₹295.17 | 23.45% | 15.57% | - |
growth is based on 5Y returns of the funds
Frequently Asked Questions
Edelweiss Msci India Domestic & World Healthcare 45 Index Fund Direct-idcw
What is the current AUM of Edelweiss Msci India Domestic & World Healthcare 45 Index Fund Direct-idcw?
As of Sun May 31, 2026, Edelweiss Msci India Domestic & World Healthcare 45 Index Fund Direct-idcw manages assets worth ₹178.1 crore
How has Edelweiss Msci India Domestic & World Healthcare 45 Index Fund Direct-idcw performed recently?
- 3 Months: 5.77%
- 6 Months: 5.24%
What is the long-term performance of Edelweiss Msci India Domestic & World Healthcare 45 Index Fund Direct-idcw?
- 3 Years CAGR: 19.31%
- 5 Years CAGR: 12.85%
- Since Inception: 15.48%
What is the portfolio composition of Edelweiss Msci India Domestic & World Healthcare 45 Index Fund Direct-idcw?
Equity: 99.67%, Debt: 0.30%, Others: 0.03%.
Who manages Edelweiss Msci India Domestic & World Healthcare 45 Index Fund Direct-idcw?
Edelweiss Msci India Domestic & World Healthcare 45 Index Fund Direct-idcw is managed by Amit Vora from Edelweiss Mutual Fund.
What is the market-cap allocation of Edelweiss Msci India Domestic & World Healthcare 45 Index Fund Direct-idcw?
Large Cap: 41.01%, Mid Cap: 38.49%, Small Cap: 20.51%.
Which are the top companies Edelweiss Msci India Domestic & World Healthcare 45 Index Fund Direct-idcw has invested in?
- Sun Pharmaceutical Industries Ltd – 11.42% of the fund's portfolio
- Eli Lilly Forgn. Eq (LLY) – 6.50% of the fund's portfolio
- Apollo Hospitals Enterprise Ltd – 5.83% of the fund's portfolio
- Divi's Laboratories Ltd – 5.27% of the fund's portfolio
- Cipla Ltd – 5.24% of the fund's portfolio
Which are the major sectors Edelweiss Msci India Domestic & World Healthcare 45 Index Fund Direct-idcw focuses on?
- Healthcare – 78.46% of the fund's portfolio
Policybazaar does not endorse rates/returns or recommend any particular insurer, fund house, AMC (Asset Management Company), insurance and mutual fund product.
Please consult your financial advisor for an informed decision.
Past performance may not be indicative of future results.
The information presented on this page is not owned or generated by Policybazaar. The data has been collected from publicly available sources and online research. We do not claim any ownership or guarantee the accuracy, completeness, or timeliness of this information. It is shared solely for the informational purpose of the viewer and should not be considered as financial advice.
Policybazaar is not acting as a financial advisor, broker, or agent for any mutual fund mentioned here.
Mutual fund investments are subject to market risks. Please read all scheme-related documents carefully before investing.
Policybazaar shall not be held responsible or liable for any losses, damages, or decisions made based on the information provided on this page.
For a complete list of mutual funds registered in India, please refer to the Securities and Exchange Board of India (SEBI) website at www.sebi.gov.in. We do not sell, endorse, or recommend any mutual fund or investment product. For a complete list of mutual funds registered in India, please refer to the Securities and Exchange Board of India (SEBI) website at www.sebi.gov.in. We do not sell, endorse, or recommend any mutual fund or investment product.
For more details on risk factors, terms, and conditions, please read the sales brochure and benefit illustration carefully before concluding a sale.
Policybazaar is a registered Insurance Broker | Registration No. 742, Registration Code No. IRDA/ DB 797/ 19, Valid till 09/06/2024, License category- Direct Broker (Life & General) |CIN: U74999HR2014PTC053454 | Registered Office - Plot No.119, Sector - 44, Gurgaon, Haryana – 122001 |Visitors are hereby informed that their information submitted on the website may be shared with insurers. Product information is authentic and solely based on the information received from the insurers.©️ Copyright 2008-2025 policybazaar.com. All Rights Reserved
^Returns as on 10th Jan’25. Tata AIA Life Top 200 ULIP Fund has delivered 18% returns over the last 10 years. Past performance is not necessarily indicative of future results. This disclaimer is specifically regarding a ULIP fund and is not related to mutual funds. Source: Morningstar.
